Future Revenue Potential Will Advance With Deepening Market Penetration and Pipeline Progress

Kiniksa Pharmaceuticals International’s analyst price target has increased from $48.86 to $50.43. Analysts cite strengthened commercial execution, robust product launches, and ongoing expansion opportunities as supporting factors for their upward revision.

Kiniksa Pharmaceuticals' analyst price target has increased from $47 to about $48.86. Analysts cite continued commercial momentum, expanding product opportunities, and a positive earnings outlook as drivers of the higher valuation.

Kiniksa Pharmaceuticals International’s consensus price target was modestly raised to $47.00 on the back of strong commercial execution, robust launch momentum, and continued outperformance, reflecting optimism on deeper penetration and expansion opportunities. Analyst Commentary Strong commercial execution driving revenue outperformance.

Driven by an improvement in net profit margin and a lower future P/E multiple, Kiniksa Pharmaceuticals International’s fair value has been revised upward, with the consensus analyst price target rising from $40.83 to $45.17. What's in the News Raised 2025 net product revenue guidance to $625–$640 million from prior $590–$605 million.